• Extend the Anagen (growth) phase of the hair
• Reduce percentage of hair in telogen (shedding) phase
• Increase hair diameter significantly after 6 months use
• Stop or reduce hair loss in approximately 70% of users after 6 months
• New hair growth in 5 to 6 months in those subjects who still had functional hair New patented composition
• Protects hair follicles against androgens which cause hair-loss in predisposed persons
• Solves the hair loss problem directly as it acts only locally, without any systemic side effects
• Positive response in most users
• Stops or significantly reduces hair loss in as little as 4 to 6 weeks
• For an executive overview of the research visit: www.ncbi.nlm.nih.gov

EUCAPIL® has been registered as a cosmetic product within the European Union and meets all of the criteria laid out in the U.K. Dti Cosmetic (Safety) Regulations 2004 and the E.U. Cosmetics Directive 76/786/EEC. It is currently available for sale as an OTC product in various countries throughout the European Union and beyond.

Hair loss in more detail
The androgenic hormones (AH) can affect the hair only via the androgenic receptor (AR), a cellular protein transcription factor which interacts with a specific region of DNA. Thus, both testosterone and its more potent analog, 5-alpha-dihydrotestosterone (DHT), must bind to the AR in the hair follicles in order to affect hair.

Antiandrogens (AA) are systemically administered drugs which block AH binding to the AR. Originally developed for the treatment of prostate cancer, these compounds, since they block AR systemically, have considerable side effects, including loss of libido and male sexual functions. These drugs cannot be used in females for the treatment of female pattern thinning (FPT) or androgenic alopecia (AGA) – not even topically – since they are well resorbed from the skin and are stable in vivo. Topical steroidal AA such as cyproterone acetate, chlormadinone acetate and spironolactone were not successful, supposedly because of poor absorption into the skin; some also have a skin irritation potential.

Currently available for treatment of androgenetic effluvium (AE) and AGA are topical minoxidil – Rogaine and its analogs. Minoxidil is an antihypertensive drug, which incidentally prevents hair loss, and to an extent, promotes regrowth, but only in the vertex scalp; the activity is tentatively explained, among others, by activation of the prostaglandin endoperoxide synthase, increase of the local blood flow, suppression of bacterial infection and/or by a modification of the AH metabolism in the dermal papilla.

Mechanism of Action of EUCAPIL® (Fluridil®) or ‘How Eucapil® actually works’: In an effort to develop a more powerful and safe inhibitor of the androgen receptor, the laboratories at Biophysica Inc. in California in collaboration with the research laboratories of a Czech biotech-pharma company, Interpharma Praha, developed a novel class of substances which proved to render the androgen receptor inactive in a novel way.

EUCAPIL® is a powerful and safe inhibitor of the androgen receptor. The basis of EUCAPIL® Hair Treatment is the patented active ingredient Fluridil® which is an androgenic receptor suppressor. There are several alopecia’s known, but the prevalent type, both in men and women, is androgenic, i.e. caused by the androgenic hormones (AH) affecting the scalp hair follicles. AH are important in the physiology of skin; they promote the growth of the beard and of the body hair throughout life. The growth of the scalp hair also depends on AH, but only in early life. It is not yet explained why AH, with increasing age, switch from promoting growth of the scalp hair to its loss, inducing conditions known as an androgenic effluvium (AE) and alopecia (AGA).

Finasteride taken orally and daily suppresses conversion of testosterone into dihydrotestosterone (DHT), thus lowering AH activity in the scalp. The studies indicate about half of the men achieve slight to moderate improvement in the anterior mid scalp and in approximately one-half, the effluvium is arrested. Side effects include decreased libido and erectile function, which disappear after drug withdrawal. No studies are yet available to prove whether such a long-term systemic manipulation of hormonal balance is harmless.

Clearly, a topically active antiandrogen suppressing rather than blocking the cutaneous AR, while not irritating and not absorbable from skin into the body, would be useful in the therapy of AH dependent cutaneous afflictions. Interpharma a.s in tandem with Biophysica Inc designed and synthesized a number of novel antiandrogens and found that some, rather than blocking, suppressed the AR in a concentration and time-dependent fashion. Some of these compounds showed extremely low or no systemic bioavailability upon oral and/or topical application. The compound with the best overall properties for topically active suppression of cutaneous androgen receptors proved to be BP-766 (Fluridil®) – the active ingredient of EUCAPIL®, since it is rapidly biodegradable into two components of high systemic and local tolerance devoid of antiandrogenic activity. It therefore offers a novel and sound concept in handling cosmetically, androgenic effluvium and incipient alopecia.

Summary:
In EUCAPIL® we have a safe, tried and tested, clinically proven, effective treatment for hair loss associated with androgenetic alopecia.

Eucapil® is available to purchase at our online store.